JP6801934B2 - 膵臓細胞の健康、生存を高め、移植転帰を改善するための抗老化グリコペプチドの使用 - Google Patents

膵臓細胞の健康、生存を高め、移植転帰を改善するための抗老化グリコペプチドの使用 Download PDF

Info

Publication number
JP6801934B2
JP6801934B2 JP2017516013A JP2017516013A JP6801934B2 JP 6801934 B2 JP6801934 B2 JP 6801934B2 JP 2017516013 A JP2017516013 A JP 2017516013A JP 2017516013 A JP2017516013 A JP 2017516013A JP 6801934 B2 JP6801934 B2 JP 6801934B2
Authority
JP
Japan
Prior art keywords
cells
isolated
transplantation
aagp
isolated pancreatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017516013A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017520275A5 (enExample
JP2017520275A (ja
Inventor
エー． エム． ジェームズ シャピロ，
エー． エム． ジェームズ シャピロ，
ラクラン グラント ヤング，
ラクラン グラント ヤング，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Protokinetix Inc
Original Assignee
Protokinetix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protokinetix Inc filed Critical Protokinetix Inc
Publication of JP2017520275A publication Critical patent/JP2017520275A/ja
Publication of JP2017520275A5 publication Critical patent/JP2017520275A5/ja
Application granted granted Critical
Publication of JP6801934B2 publication Critical patent/JP6801934B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/90—Polysaccharides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physiology (AREA)
  • Virology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
JP2017516013A 2014-06-04 2015-06-02 膵臓細胞の健康、生存を高め、移植転帰を改善するための抗老化グリコペプチドの使用 Active JP6801934B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462007626P 2014-06-04 2014-06-04
US62/007,626 2014-06-04
PCT/CA2015/050509 WO2015184544A1 (en) 2014-06-04 2015-06-02 Use of anti-aging glycopeptides to enhance pancreatic cell health, survival and improve transplant outcome

Publications (3)

Publication Number Publication Date
JP2017520275A JP2017520275A (ja) 2017-07-27
JP2017520275A5 JP2017520275A5 (enExample) 2017-09-07
JP6801934B2 true JP6801934B2 (ja) 2020-12-16

Family

ID=54765902

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017516013A Active JP6801934B2 (ja) 2014-06-04 2015-06-02 膵臓細胞の健康、生存を高め、移植転帰を改善するための抗老化グリコペプチドの使用

Country Status (8)

Country Link
US (4) US20150352155A1 (enExample)
EP (1) EP3152297A4 (enExample)
JP (1) JP6801934B2 (enExample)
KR (1) KR102411834B1 (enExample)
CN (1) CN106661549B (enExample)
AU (1) AU2015271608B9 (enExample)
NZ (1) NZ727749A (enExample)
WO (1) WO2015184544A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3407876B1 (en) 2016-01-27 2022-01-12 Protokinetix Inc. Use of anti-aging glycoprotein for enhancing survival of neurosensory precursor cells
SI3411047T1 (sl) 2016-02-04 2021-09-30 Czap Research And Development, Llc Sredstva za nadzorovano sproščeni in stratificirani kompleks vključitve ciklodekstrina
KR20220137037A (ko) * 2020-01-24 2022-10-11 프로토키네틱스 인코포레이티드 이식편의 면역 거부의 억제를 위한 항-노화 글리코펩타이드들의 사용
CN115568282A (zh) * 2020-03-10 2023-01-03 普罗托基尼蒂克有限公司 抗衰老糖肽治疗干眼症、视网膜退行性疾病或眼部炎症的用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2878851B1 (fr) * 2004-12-02 2007-02-09 Inst Nat Sciences Appliq Composes c-glycopeptides gem-difluores, leur preparation et leur utilisation en cryochirurgie et/ou cryopreservation
FR2900656A1 (fr) * 2006-05-03 2007-11-09 Inst Nat Sciences Appliq Composes c-glycopeptides gem-difluores, leur preparation et leur utilisation notamment pour la preservation de materiaux biologiques

Also Published As

Publication number Publication date
JP2017520275A (ja) 2017-07-27
NZ727749A (en) 2023-04-28
EP3152297A1 (en) 2017-04-12
US20170360844A1 (en) 2017-12-21
CA2950963A1 (en) 2015-12-10
KR102411834B1 (ko) 2022-06-21
CN106661549A (zh) 2017-05-10
AU2015271608A1 (en) 2017-01-12
WO2015184544A1 (en) 2015-12-10
US20230414675A1 (en) 2023-12-28
AU2015271608B2 (en) 2021-05-27
KR20170023029A (ko) 2017-03-02
US20150352155A1 (en) 2015-12-10
EP3152297A4 (en) 2018-01-31
AU2015271608B9 (en) 2021-06-17
CN106661549B (zh) 2022-02-11
US20210023142A1 (en) 2021-01-28

Similar Documents

Publication Publication Date Title
US20230414675A1 (en) Use of anti-aging glycopeptides to enhance pancreatic cell health, survival and improve transplant outcome
RU2733950C1 (ru) Комбинация для лечения рака предстательной железы, фармацевтическая композиция и способ лечения
US20210169830A1 (en) Reagents, compositions and methods for improving viability and function of cells, tissues and organs
Chang et al. Ex-vivo generation of drug-eluting islets improves transplant outcomes by inhibiting TLR4-Mediated NFkB upregulation
JP2024041813A (ja) ミトコンドリアのリンパ器官への移植およびそのための組成物
WO2017209270A1 (ja) ２５－ヒドロキシコレステロール又はその類縁体コレステロールを有効成分として含有してなる、活性化されたｔ細胞及び／又はｂ細胞に選択的な細胞死誘導剤又は細胞死促進剤
CA2950963C (en) Use of anti-aging glycopeptides to enhance pancreatic cell health, survival and improve transplant outcome
US20170340689A1 (en) Titrated extracts of cynara scolymus for use in the treatment of mesothelioma
US20230142705A1 (en) Use of anti-aging glycopeptides for inhibition of immune rejection of a graft
HK1237814B (zh) 抗衰老糖肽在增强胰腺细胞健康、存活以及改善移植效果的应用
HK1237814A1 (en) Use of anti-aging glycopeptides to enhance pancreatic cell health, survival and improve transplant outcome
KR102242040B1 (ko) 줄기세포의 티오레독신 발현을 증진시키는 방법
KR101999842B1 (ko) 지방유래 줄기세포 추출물을 유효성분으로 함유하는 염증성 질환 예방 또는 치료용 조성물
CN114599379A (zh) 一种用于预防或治疗脓毒症的药物组合物、试剂盒及其应用和治疗方法
KR20180080585A (ko) 현적 배양 기술을 이용한 인슐린 분비 능력 향상 세포 클러스터 제조방법
Yoshimatsu et al. The impact of allogenic blood transfusion on the outcomes of total pancreatectomy with islet autotransplantation
JP2016138087A (ja) 抗腫瘍剤
IT201900007446A1 (it) Composizione comprendente citrato e carnitina in grado di attivare la produzione della proteina klotho
Zhu et al. The effects of testicular aging on Leydig cells and the application of stem cells in restoring Leydig cells function
KR20240061203A (ko) 자연살해세포 및 atra-나노겔을 유효성분으로 포함하는 섬유증 예방 및 치료용 약학 조성물
JP5727167B2 (ja) Ｎｃｘを標的とした単離膵島ならびに移植膵島障害の新規制御法
JP2021088545A (ja) 環状ペプチド化合物、キヌレニン産生阻害剤及び医薬組成物
Sakata et al. Spleen, as an optimal site for islet transplantation 2

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170710

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180525

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190625

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20190920

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190925

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200114

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200602

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201027

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201124

R150 Certificate of patent or registration of utility model

Ref document number: 6801934

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250